Flexion Therapeutics, Inc. (FLXN) Receives Average Rating of “Buy” from Brokerages
Flexion Therapeutics, Inc. (NASDAQ:FLXN) has earned a consensus recommendation of “Buy” from the eleven research firms that are covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation, seven have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $32.50.
Several equities research analysts have recently issued reports on the company. Northland Securities reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Flexion Therapeutics in a research note on Wednesday. Zacks Investment Research upgraded Flexion Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, August 28th. Needham & Company LLC reissued a “buy” rating and set a $36.00 target price on shares of Flexion Therapeutics in a research report on Sunday, September 17th. ValuEngine raised Flexion Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Finally, Royal Bank Of Canada set a $44.00 price target on Flexion Therapeutics and gave the company a “buy” rating in a report on Monday, September 11th.
In other Flexion Therapeutics news, insider Yamo Deniz purchased 3,000 shares of the firm’s stock in a transaction that occurred on Friday, September 1st. The stock was purchased at an average cost of $24.15 per share, with a total value of $72,450.00. Following the purchase, the insider now owns 5,000 shares of the company’s stock, valued at $120,750. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last quarter, insiders bought 5,375 shares of company stock worth $131,575. Company insiders own 15.98% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Teachers Advisors LLC increased its stake in Flexion Therapeutics by 21.2% in the 4th quarter. Teachers Advisors LLC now owns 43,468 shares of the specialty pharmaceutical company’s stock worth $827,000 after buying an additional 7,610 shares during the period. Wells Fargo & Company MN lifted its holdings in Flexion Therapeutics by 25.1% during the 1st quarter. Wells Fargo & Company MN now owns 124,717 shares of the specialty pharmaceutical company’s stock valued at $3,356,000 after buying an additional 25,047 shares in the last quarter. Swiss National Bank lifted its holdings in Flexion Therapeutics by 13.2% during the 1st quarter. Swiss National Bank now owns 35,911 shares of the specialty pharmaceutical company’s stock valued at $966,000 after buying an additional 4,200 shares in the last quarter. Ameriprise Financial Inc. bought a new stake in Flexion Therapeutics during the 1st quarter valued at about $1,246,000. Finally, Parametric Portfolio Associates LLC boosted its position in Flexion Therapeutics by 79.0% in the 1st quarter. Parametric Portfolio Associates LLC now owns 27,600 shares of the specialty pharmaceutical company’s stock valued at $743,000 after buying an additional 12,181 shares during the period. Hedge funds and other institutional investors own 83.26% of the company’s stock.
Flexion Therapeutics (FLXN) traded down 1.28% during trading on Wednesday, reaching $26.15. The company had a trading volume of 1,661,246 shares. The firm’s 50 day moving average is $24.20 and its 200 day moving average is $22.44. The company’s market capitalization is $834.32 million. Flexion Therapeutics has a one year low of $15.93 and a one year high of $29.41.
Flexion Therapeutics (NASDAQ:FLXN) last released its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.91) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.80) by ($0.11). On average, equities research analysts predict that Flexion Therapeutics will post ($3.74) earnings per share for the current year.
About Flexion Therapeutics
Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.
Receive News & Stock Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related stocks with our FREE daily email newsletter.